Trials / Completed
CompletedNCT00195689
Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis
A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Moderate to Severely Active Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Human anti-TNF monoclonal antibody/adalimumab |
Timeline
- Start date
- 2003-08-01
- First posted
- 2005-09-20
- Last updated
- 2007-08-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00195689. Inclusion in this directory is not an endorsement.